FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
US Seeks Gulf Support for Iran Peace Deal Amid Regional Tensions 
Israel Heritage Bill Sparks Annexation Concerns in West Bank 
Bessent Says U.S. Must Strengthen Supply Chains and Economic Security 
US Supreme Court Strikes Down Hawaii Gun Carry Law on Private Property 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
ICC Judges Sue Trump Administration Over Sanctions, Calling Measures Unlawful 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access 
Samsung, SK Hynix to Unveil Record AI and Semiconductor Investment Plans Worth Over $646 Billion 
Iran Attack in Strait of Hormuz Pushes Oil Prices Higher 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Novo Nordisk has named U.S. pharmaceutical executive Greg Miley as its new Global Head of Corporate Affairs, a strategic move as the Danish drugmaker faces heightened scrutiny from U.S. President Donald Trump over drug pricing. Miley, formerly Senior Vice President of Government Affairs at AbbVie, announced his appointment on LinkedIn, with Novo Nordisk confirming the news to Reuters.
The company stated that Miley will officially join in early November, overseeing global communications and public affairs. His extensive experience in the U.S. pharmaceutical sector is expected to help Novo strengthen its political and regulatory strategies in its largest market—the United States. A company source noted that Miley’s top priority will be managing relations with the Trump administration, which has recently intensified pressure on pharmaceutical firms to reduce prices.
Miley’s appointment aligns with new CEO Mike Doustdar’s efforts to regain investor confidence through a broad restructuring initiative aimed at improving competitiveness in the growing obesity drug market, particularly against Eli Lilly. The overhaul involves cutting about 9,000 jobs worldwide, including 5,000 in Denmark and several in the U.S.
In his LinkedIn post, Miley expressed optimism about enhancing Novo’s global communication and public affairs, noting his upcoming relocation to Denmark. Industry insiders say other major pharma companies have also been recruiting public affairs experts with strong Republican ties to navigate Washington’s policy landscape.
Shares of Novo Nordisk and Eli Lilly dropped on Friday following Trump’s statement that the price of Ozempic—Novo’s diabetes drug containing the same ingredient as its popular weight-loss drug Wegovy—would be lowered.
Miley brings nearly two decades of experience in pharmaceutical government relations, with past roles at Abbott and Pfizer, making him a pivotal figure in Novo’s next phase of global engagement.
